| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2025-04-08 15:51:01 UTC |
|---|
| Updated at | 2025-07-24 18:35:52 UTC |
|---|
| NP-MRD ID | NP0350921 |
|---|
| Natural Product DOI | https://doi.org/10.57994/3906 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Comp3 |
|---|
| Description | Comp3 was first documented in 2021 (PMID: 33495861). Based on a literature review a small amount of articles have been published on Comp3 (PMID: 37702159) (PMID: 36816262) (PMID: 37513188) (PMID: 38822803). |
|---|
| Structure | CC(C)(C=C)C1=C(C[C@@H]2NC(=O)[C@@H]3CC[C@@H](NC(N)=N)N3C2=O)C2=C(N1)C=CC=C2 InChI=1S/C22H28N6O2/c1-4-22(2,3)18-13(12-7-5-6-8-14(12)25-18)11-15-20(30)28-16(19(29)26-15)9-10-17(28)27-21(23)24/h4-8,15-17,25H,1,9-11H2,2-3H3,(H,26,29)(H4,23,24,27)/t15-,16-,17-/m0/s1 |
|---|
| Synonyms | Not Available |
|---|
| Chemical Formula | C22H28N6O2 |
|---|
| Average Mass | 408.5060 Da |
|---|
| Monoisotopic Mass | 408.22737 Da |
|---|
| IUPAC Name | N-[(3S,6S,8aS)-3-{[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methyl}-1,4-dioxo-octahydropyrrolo[1,2-a]pyrazin-6-yl]guanidine |
|---|
| Traditional Name | N-[(3S,6S,8aS)-3-{[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methyl}-1,4-dioxo-hexahydropyrrolo[1,2-a]pyrazin-6-yl]guanidine |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC(C)(C=C)C1=C(C[C@@H]2NC(=O)[C@@H]3CC[C@@H](NC(N)=N)N3C2=O)C2=C(N1)C=CC=C2 |
|---|
| InChI Identifier | InChI=1S/C22H28N6O2/c1-4-22(2,3)18-13(12-7-5-6-8-14(12)25-18)11-15-20(30)28-16(19(29)26-15)9-10-17(28)27-21(23)24/h4-8,15-17,25H,1,9-11H2,2-3H3,(H,26,29)(H4,23,24,27)/t15-,16-,17-/m0/s1 |
|---|
| InChI Key | WVLIWDCKPOTOKZ-ULQDDVLXSA-N |
|---|
| Experimental Spectra |
|---|
|
| | Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
|---|
| HSQC NMR | [1H, 13C] NMR Spectrum (2D, 500 MHz, C2D6OS, experimental) | niwakanji0218@gmail.com | University of California, Los Angeles | Kanji Niwa | 2025-04-08 | View Spectrum | | HMBC NMR | [1H, 13C] NMR Spectrum (2D, 500 MHz, C2D6OS, experimental) | niwakanji0218@gmail.com | University of California, Los Angeles | Kanji Niwa | 2025-04-08 | View Spectrum | | COSY NMR | [1H, 1H] NMR Spectrum (2D, 500 MHz, C2D6OS, experimental) | niwakanji0218@gmail.com | University of California, Los Angeles | Kanji Niwa | 2025-04-08 | View Spectrum | | ROESY NMR | [1H, 1H] NMR Spectrum (2D, 500 MHz, C2D6OS, experimental) | niwakanji0218@gmail.com | University of California, Los Angeles | Kanji Niwa | 2025-04-08 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, C2D6OS, experimental) | niwakanji0218@gmail.com | University of California, Los Angeles | Kanji Niwa | 2025-04-08 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, C2D6OS, experimental) | niwakanji0218@gmail.com | University of California, Los Angeles | Kanji Niwa | 2025-04-08 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, C2D6OS, experimental) | niwakanji0218@gmail.com | University of California, Los Angeles | Kanji Niwa | 2025-04-08 | View Spectrum |
| | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | Not Available |
|---|
| Chemical Taxonomy |
|---|
| Classification | Not classified |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Naskar A, Bhanja KK, Roy RK, Patra N: Structural insight into G2019S mutated LRRK2 kinase and brain-penetrant type I inhibitor complex: a molecular dynamics approach. J Biomol Struct Dyn. 2024;42(19):10129-10149. doi: 10.1080/07391102.2023.2255675. Epub 2023 Sep 13. [PubMed:37702159 ]
- Rampogu S, Shaik B, Kim JH, Jung TS, Ha MW, Lee KW: Explicit molecular dynamics simulation studies to discover novel natural compound analogues as Mycobacterium tuberculosis inhibitors. Heliyon. 2023 Jan 30;9(2):e13324. doi: 10.1016/j.heliyon.2023.e13324. eCollection 2023 Feb. [PubMed:36816262 ]
- Khan S, Fakhar Z, Ahmad A: Targeting ebola virus VP40 protein through novel inhibitors: exploring the structural and dynamic perspectives on molecular landscapes. J Mol Model. 2021 Jan 25;27(2):49. doi: 10.1007/s00894-021-04682-8. [PubMed:33495861 ]
- Yin Z, Liu S, Yang X, Chen M, Du J, Liu H, Yang L: LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study. Molecules. 2023 Jul 10;28(14):5315. doi: 10.3390/molecules28145315. [PubMed:37513188 ]
- Naskar A, Roy RK, Srivastava D, Patra N: Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease. J Phys Chem B. 2024 Jul 18;128(28):6657-6669. doi: 10.1021/acs.jpcb.4c00335. Epub 2024 Jun 1. [PubMed:38822803 ]
|
|---|